{"id":605416,"date":"2024-06-04T04:20:43","date_gmt":"2024-06-04T08:20:43","guid":{"rendered":"https:\/\/platohealth.ai\/moderna-and-msd-share-encouraging-three-year-data-from-trial-of-melanoma-therapy\/"},"modified":"2024-06-04T07:50:07","modified_gmt":"2024-06-04T11:50:07","slug":"moderna-and-msd-share-encouraging-three-year-data-from-trial-of-melanoma-therapy","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/moderna-and-msd-share-encouraging-three-year-data-from-trial-of-melanoma-therapy\/","title":{"rendered":"Moderna and MSD share encouraging three-year data from trial of melanoma therapy","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
Pharmaceutical companies Moderna<\/a> and Merck & Co (MSD) have announced positive results<\/a> from the Phase IIb KEYNOTE-942\/mRNA-4157-P201 study of mRNA-4157 (V940) plus Keytruda to treat high-risk melanoma (stage III\/IV) following complete resection.<\/p>\n <\/p>\n mRNA-4157 is an investigational messenger ribonucleic acid (mRNA) individualised neoantigen therapy (INT).<\/p>\n Access the most comprehensive Company Profiles <\/figure>\n
\n on the market, powered by GlobalData. Save hours of research. Gain competitive edge.<\/p>\n